Choroidal Neovascularization in Pathologic Myopia: Intravitreal Ranibizumab Versus Bevacizumab—A Randomized Controlled Trial
Authors:
- Magda GharbiyaMGMagda Gharbiya
- Rosalia GiustolisiRGRosalia Giustolisi
- Francesca AllieviFAFrancesca Allievi
- Nicoletta FantozziNFNicoletta Fantozzi
- Luigi MazzeoLMLuigi Mazzeo
- Vittorio ScavellaVSVittorio Scavella
- Corrado Balacco GabrieliCGCorrado Balacco Gabrieli
- 1 March 2010
- journal article
- research article
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 149 (3) , 458-464.e1
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- INTRAVITREAL RANIBIZUMAB FOR THE PRIMARY TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGIC MYOPIARetina, 2009
- Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cellsExperimental Eye Research, 2009
- Comparison of the optical coherence tomographic features of choroidal neovascular membranes in pathological myopia versus age-related macular degeneration, using quantitative subanalysisBritish Journal of Ophthalmology, 2008
- Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectivenessBritish Journal of Ophthalmology, 2007
- Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot studyBritish Journal of Ophthalmology, 2007
- The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwideBritish Journal of Ophthalmology, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- SAFETY OF INTRAVITREAL INJECTION OF BEVACIZUMAB IN RABBIT EYESRetina, 2006
- Errors in Retinal Thickness Measurements Obtained by Optical Coherence TomographyOphthalmology, 2006
- Bevacizumab suppresses choroidal neovascularisation caused by pathological myopiaBritish Journal of Ophthalmology, 2005